Clinical Advisory Board

Paul G. Richardson, MD

Professor, RJ Corman Professor of Medicine HMS at the Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.

Dr. Richardson currently holds leadership positions in several professional bodies and serves several Editorial Boards. He serves on the Steering Committee and Project Review Committee for the Multiple Myeloma Research Consortium (MMRC). He chairs the Multiple Myeloma Committee for the Alliance for Clinical Trials in Oncology (the former CALG).


Dr. Richardson has published more than 340 original articles and more than 260 reviews, chapters, and editorials in leading peer-reviewed journals, and he has been a leader in the clinical development of bortezomib, lenalidomide, panobinostat, pomalidomide, elotuzumab, and daratumumab.


Holdings in Oncopeptides: -

Lori A Kunkel, MD

Dr., MD

Dr. Lori A Kunkel, MD, currently works as an independent consultant for several companies. She has more than 20 years of experience in clinical development, commercialization of pharmaceuticals and has worked as Chief Medical Officer at a number of oncology companies including Pharmacyclics and Proteolix. Dr Kunkel was previously active at the UCLA School of Medicine.


Holdings in Oncopeptides: -

Axel Glasmacher


Professor Axel Glasmacher, MD, was until recently Senior Vice President and Head of the Global Clinical Research and Development Hematology Oncology at Celgene where he has worked in various global roles for more than ten years.


Prior to that, Professor Glasmacher worked in hematology-oncology at the University Hospital in Bonn.


Holdings in Oncopeptides: -

Christian Jacques

Christian Jacques, MD


Dr. Christian Jacques, MD, is a Hematologist-Oncologist (UCL, 1988) who has more than 25 years of experience in clinical development of new drug candidates.


Dr. Jacques has a broad industrial experience and has worked in several global pharmaceutical companies including Novartis, J & J, and most recently as Global Myeloma Therapeutic Area Head at Celgene Inc. Dr. Jacques is Chief Scientific Officer at Oncopeptides since 2018.


Holdings in Oncopeptides: 200,000 options**

** The options entitles to one share per option in accordance with existing terms. For more information and terms please read under Corporate - Governance – Remuneration.


Holdings in Oncopeptides AB (publ) as of January 15, 2021.